22 results about "Type specific" patented technology

Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.

This disclosure is directed to a targeted delivery vehicle that can deliver a cargo to a cell of interest. The targeted delivery vehicle has a fusogen and a targeting domain which are embedded in a lipid bilayer membrane that forms a vesicle, and a cargo within the vesicle. The disclosure is also directed to methods for targeted delivery of cargo using the targeted delivery vehicle described herein.

The invention provides an O-type foot-and-mouth disease nanoparticle antigen NP-OVPn as well as a preparation method and application thereof. The NP-OVPn provided by the invention is obtained by the following steps: after intracellular self-assembled O-type foot-and-mouth disease nanoparticle antigen NP-OVPn-T is subjected to TEV enzyme cleavage, removing T fusion-promoting tag protein through nickel affinity chromatography purification, and enabling antigen epitopes to be fully exposed on the surface of nanoparticle carrier protein NP. According to the FMDV O-type NP-OVPn nanoparticle antigen, three structural proteins of FMDV O-type VP1, VP2 and VP3 are displayed at the same time in the form of nanoparticles, the FMDV O-type NP-OVPn nanoparticle antigen can well and uniformly react with antibodies generated after immunization or infection of three animals including pigs, cattle and sheep, and the problem that the source of the FMDV O-type antigen is limited in FMDV clinical diagnosis is solved. The invention also provides a vaccine developed on the basis of the NP-OVPn nanoparticle antigen, and an FMDV O-type LB-ELISA antibody detection kit. The kit can be simultaneously used for quantitative detection of FMDV O-type specific antibodies from three different animals, namely pigs, cows and sheep, and has the advantages of high sensitivity, good specificity and high accuracy.

The present disclosure provides methods and compositions useful for screening AAV capsid libraries for desired characteristics, such as cell-type specific tropisms. Each AAV capsid library disclosed herein includes a known promoter (e.g., a ubiquitous or cell-type specific promoter) and barcode made up of silent mutations, allowing multiple AAV capsid variant libraries to be pooled and administered in a single experiment.

A viral vector having a lipid bilayer envelope is provided, comprising a cell-type specific antibody-binding domain presented outside the envelope, a viral envelope protein presented outside the envelope capable of promoting infection of the same cell type, and a nucleic acid molecule containing a promoter expressible in the same cell type. Furthermore, a method for producing the viral vector and a method for modifying cells and treating diseases / conditions using this viral vector are also provided.

The present invention relates to the field of modular platforms, such as viral vectors. In particular, the present invention relates to a recombinant adeno- associated virus (AAV) capsid or particle comprising an engineered virion protein (VP), wherein the engineered VP comprises at least one cell-type specific binding moiety located in variable region 8 (VR8). The invention also relates to a recombinant AAV particle for use as a medicament.

The present invention is related to the generation and use of secreted fusogenic vesicles incorporating engineered viral glycoprotein, or engineered endogenous human fusiogenic proteins derived from human endogenous retroviruses proteins, such vesicles being generally referred to as “gectosomes.” The present invention is further related to the use of engineered gectosomes to deliver therapeutic molecules or antigens to cell and tissues in a targeted manner, as well as systems and methods for using gectosomes to screen for therapeutically relevant compounds or therapeutic antibodies.

The present invention relates to compositions for effective targeted delivery of a gene editing agent or transcriptional modulator to a target cell, as well as methods of use thereof for the treatment of diseases including cancer and genetic diseases. In some embodiments, the invention relates to a composition for targeted delivery of a genome editing agent or transcriptional modulator, wherein the composition comprises a delivery vehicle comprising a targeting moiety specific for binding to a cell or tissue of interest. In some embodiments, the genome editing agent comprises a ribonucleoprotein (RNP) complex comprising a CRISPR Cas protein and a guide RNA.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

The present disclosure provides, in part, engineered tyrosine hydroxylase (TH) promoters, vectors (e.g., viral vectors) comprising the engineered TH promoters, and uses thereof for improving neuronal-type specific epigenome editing of neurodegenerative disease relevant genes (e.g., SNCA).

The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.

To provide methods of profiling gene and protein expression of a plurality of nuclei from a single cell type.SOLUTION: Provided is a method of profiling nuclear epigenetic expression and / or nuclear structure, the method comprising: (a) processing a tissue sample containing a plurality of cell types to expose nuclei, the tissue sample comprising brain tissue, brain stem tissue, and / or spinal cord tissue; (b) contacting the nuclei with two or more affinity labels that bind to different nucleic acid transcripts or proteins that are specific to the nuclei of a cell type in the tissue sample to label the nuclei, the nucleic acid transcripts or proteins being encoded by genes selected from a specific group; (c) purifying the nuclei labeled with two or more affinity labels; and (d) (i) collecting information regarding histone modifications, binding of transcription factors, and DNA modifications for the labeled nuclei to profile the epigenetic expression of the nuclei, and / or (ii) collecting information on the chromosomal structure of the labeled nuclei to profile the nuclear structure.SELECTED DRAWING: Figure 1

An analyzer may be adapted to verify its operation using a control sample containing synthetic particles. Such an analyzer may be adapted to obtain particle representations from the sample and to obtain particle classifications that classify the particles as types specific to the control sample. The analyzer may also be adapted to perform a control-specific process on the sample and generate an analytical output for the sample based on the results of the control-specific process.

The invention relates to methods of tracking the movement of an amino acid of interest or a metabolite thereof in a eukaryotic multicellular structure, methods of diagnosis and screening related thereto, and nucleic acids encoding amino-acid stereo- isomerase for use therein.

The embodiment of the invention discloses a primer group, a kit and a detection method for genetic typing detection of Leptin gene editing animals, and belongs to the technical field of biology. The primer group comprises public primers Leptin-F and Leptin-R as shown in SEQ ID NO: 2 to SEQ ID NO: 3, a wild type specific primer OB-R as shown in SEQ ID NO: 4, and a mutant type specific primer OB-F as shown in SEQ ID NO: 5. The Leptin gene editing animal genotyping scheme established by the ARMS-PCR technology breaks through the bottleneck of the traditional method with the advantages of high efficiency, economy and accuracy, provides key technical support for the research of obesity and metabolic diseases, and has important scientific value and practical application significance.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

Methods of detecting cell-type-specific liver damage in a subject who received a liver transplant, the method comprising sequencing cell-free DNA (cfDNA) in a sample from the subject; determining cell-type from which the cfDNA originated by identifying methylation patterns in nucleotide sequence of one or more portions of the cfDNA that contains methylation sites, in which the cell-type is determined when the methylation pattern in the one or more portions is the same as a cell-type specific methylation pattern; and measuring the quantity of the cfDNA of the determined cell-type. The cell-type-specific liver damage is detected when the measured quantity of the cfDNA of the determined cell-type is greater as compared to a quantity of cfDNA of the determined cell-type in subjects without liver transplant damage. Methods also relating to treatment of subjects who received a liver transplant.

The invention pertains to an inducible CRISPR system for controlling expression of a CRISPR complex with an inducible fusion promoter. One embodiment of the invention provides HIV LTR-minimal Drosophila hsp70 fusion promoter that can be used for inducible co-expression of gRNA and Cas9 in HIV-infected cells to target cellular cofactors such as Cyclin T1. A single introduction of such embodiment leads to sustained suppression of HIV replication in stringent, chronically infected HeLa-CD4 cell lines as well as in T-cell lines. In another embodiment, the invention further relates to enhancement of HIV suppression by incorporating cis-acting ribozymes immediately upstream of the gRNA in the inducible CRISPR system construct. The inducible fusion promoter is adaptable for other tissue- or cell-type specific expression of the inducible CRISPR system.

The invention relates to methods of tracking the movement of an amino acid of interest or a metabolite thereof in a eukaryotic multicellular structure, methods of diagnosis and screening related thereto, and nucleic acids encoding amino-acid stereo- isomerase for use therein.

The disclosure relates to betaretroviruses (genus Betaretrovirus), and recombinant betaretroviral envelope (rENV) protein for use in viral vector platforms, an engineered delivery vehicle and gene therapy, their associated methods of use and manufacture. In particular, the present disclosure provides compositions and methods to tune betavirus envelope proteins such that they target a particular cell surface receptor; i.e., are cell and / or tissue-type specific, allowing for better site-specific transgene delivery and expression.

The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.

The invention provides a type A foot-and-mouth disease nanoparticle antigen NP-AVPn, a preparation method and an application. The NP-AVPn provided by the invention is obtained by carrying out TEV enzyme cracking on intracellular self-assembled A type foot-and-mouth disease nano-particle antigen NP-AVPn-T, and then carrying out nickel affinity chromatography purification to remove T fusion-promoting tag protein, so that antigen epitopes are fully exposed on the surface of nano-particle carrier protein NP. According to the FMDVA type NP-AVPn nanoparticle antigen disclosed by the invention, three structural proteins of FMDVA type VP1, VP2 and VP3 are simultaneously displayed in a nanoparticle form, so that the FMDVA type NP-AVPn nanoparticle antigen can be simultaneously subjected to good and uniform reaction with antibodies generated after immunization or infection of three animals of pigs, cattle and sheep, and the problem that the FMDVA type antigen is limited in source in FMDV clinical diagnosis is solved. The invention also provides a vaccine developed based on the NP-AVPn nanoparticle antigen and an FMDVA type LB-ELISA antibody detection kit, and the kit can be simultaneously used for quantitative detection of FMDVA type specific antibodies from three different animals, namely pigs, cows and sheep, and has the advantages of high sensitivity, good specificity and high accuracy.